1. Generics Bulletin
  2. >>Business
  3. >>Deals

Aurobindo Seeks To Boost India Business With Veritaz Acquisition

Indian Pharma Firm Has Paid INR1.71bn For Domestic Formulations Business

 
• By Chloe Kent

Aurobindo is looking to grow its business in India by acquiring Veritaz’s domestic formulations operations in a $22.4m slump sale.

Indian national flag with dollar bills
Aurobindo's India business currently contributes to 12% of its revenue • Source: Alamy

India’s Aurobindo Pharma Limited has entered into a definitive agreement with Veritaz to acquire its domestic formulations business for a cash consideration of INR1.71bn ($22.4m). The transaction, which will be in effect from 1 April – and is expected to close by May – includes associated inventory, intellectual property and contracts and is made with no debt liability or cash benefits.

The company expects the acquisition to act as a launch pad to support its business across India, particularly in the biosimilars market

More from Deals

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business